OB
OBSEF.US ObsEva SA
- Market cap
- USD 11.7K
- P/E
- -
- P/B
- 0.00x
- ROE
- -352.2%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the fiscal year ending Dec 2022.
Is OBSEF.US undervalued?
Graham numberThe Graham number of ObsEva SA cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ObsEva SA fundamental analysis
No fundamental analysis for ObsEva SA yet.
ObsEva SA stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ObsEva SA
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
Full company profileObsEva SA financial statements
ObsEva SA annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | 0.00 | 0.00 | 22.2M | 19.6M |
| Operating Income | -107M | -79.7M | -56.6M | -15.7M |
| EBITDA | - | - | -48.7M | -20.1M |
| Net Income | -109M | -83.0M | -53.0M | -29.9M |
| EPS | -2.44 | -1.44 | -0.66 | -0.28 |
| Balance Sheet | ||||
| Total Assets | 104M | 65.4M | 64.5M | 16.5M |
| Total Liabilities | 55.0M | 57.1M | 51.6M | 8.06M |
| Shareholders' Equity | 49.0M | 8.35M | 12.9M | 8.48M |
| Cash & Short-term Investments | 69.4M | 31.2M | 54.7M | 8.42M |
| Cash Flow | ||||
| Operating Cash Flow | -90.6M | -70.8M | -50.4M | -23.1M |
| Capital Expenditure | 5.05M | 5.00K | 14.0K | 0.00 |
| Free Cash Flow | -95.7M | -70.8M | -50.4M | -23.1M |
| Ratios | ||||
| ROE | -222.2% | -993.1% | -410.5% | -352.2% |
| ROA | -104.7% | -126.8% | -82.1% | -180.6% |
| Net Profit Margin | - | - | -238.6% | -152.2% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ObsEva SA dividends
ObsEva SA has not paid dividends in the last 5 fiscal years.
Last stock split: 13:1 on Dec 6, 2016.
Who owns ObsEva SA
- Insiders 8.92%
- Institutions 1.34%
- Public & others 89.74%
- Shares outstanding 117M
- Free float 103M
ObsEva SA company profile
- Company name
- ObsEva SA
- Ticker
- OBSEF.US
- ISIN
- CH1260041939
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 15
- Fiscal year end
- December
- Address
- Chemin des Aulx, 12, Geneva, Switzerland, 1228
- Phone
- 41 22 552 38 40
- Website
- obseva.com
About ObsEva SA
ObsEva SA, a biopharmaceutical company, focuses on the development of novel therapies to improve women's reproductive health. It develops Nolasiban, an oral oxytocin receptor agonist for improving clinical pregnancy and live birth rates in women undergoing in-vitro fertilization. The company was founded in 2012 and is headquartered in Geneva, Switzerland.
ObsEva SA management
3- Dr. Ernest Loumaye M.D., OB/GYN, Ph.D.Co-Founder & Chairman · born 1952
- Mr. Fabien Lefebvre de LadonchampsCEO & Director · born 1979
- Ms. Delphine RenaudPersonal Assistant to the CSO and Head of R&D